Call for Abstract

2nd World Conference on Vascular Dementia & Movement Disorders, will be organized around the theme “Advances and Innovations in Dementia”

VASCULAR DEMENTIA 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in VASCULAR DEMENTIA 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Neurodegenerative disease is an umbrella term for a range of conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Examples of neurodegenerative diseases include Parkinson’s, Alzheimer’s, and Huntington’s disease.
  • Track 1-1Epilepsy/Seizures
  • Track 1-2Stroke
  • Track 1-3Brain Injury
  • Track 1-4Traumatic brain injury: TBI
  • Track 1-5Parkinson’s disease (PD) and PD-related disorders
  • Track 1-6Prion disease
  • Track 1-7Motor neurone diseases (MND)
  • Track 1-8Huntington’s disease (HD)
  • Track 1-9Spinocerebellar ataxia (SCA)
  • Track 1-10Spinal muscular atrophy (SMA)
Neuropharmacology is an extremely wide locale of science that includes numerous parts of the sensory system from single neuron control to whole ranges of the cerebrum, spinal line, and fringe nerves. To better comprehend the premise behind medication advancement, one should first see how neurons speak with each other. This article will concentrate on both behavioral and atomic neuropharmacology; the real receptors, particle channels, and neurotransmitters controlled through medication activity and how individuals with a neurological issue advantage from this medication activity.
  • Track 2-1Neuroscience and neuropharmacology
  • Track 2-2Neurochemical interaction
  • Track 2-3Anti-dementia drugs
  • Track 2-4Novel drug target for the treatment of dementia
  • Track 2-5Novel therapeutics molecule
Dementia is not a specific disease. It's an overall term that describes a wide range of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities. Alzheimer's disease. Vascular dementia, which occurs after a stroke, is the second most common dementia type. But there are many other conditions that can cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. Dementia is a syndrome that involves severe loss of cognitive abilities as a result of disease or injury. Dementia caused by traumatic brain injury is often static, whereas dementia caused by neurodegenerative disorders, such as Alzheimer's disease.
  • Track 3-1Primary mental health care and nursing
  • Track 3-2Novel therapeutics technology
  • Track 3-3Novel therapeutics strategies for Dementia
  • Track 3-4Mixed dementia
  • Track 3-5Frontotemporal dementia
  • Track 3-6Neurogenesis in dementia
  • Track 3-7Global prevalence of dementia
  • Track 3-8Radiation Therapy And Chemotherapy
Lewy body is also known as dementia with Lewy bodies, with Lewy body dementia is the second most common type of progressive dementia after Alzheimer's disease dementia. Protein deposits, called Lewy bodies, develop in nerve cells in the brain regions involved in thinking, memory and movement (motor control). Lewy body dementia is also causes a progressive decline in mental abilities. The people with Lewy body dementia may experience visual hallucinations and changes in the alertness and attention and other effects include Parkinson's disease-like symptoms such as rigid muscles, slow movement and tremors.
  • Track 4-1Risk factor of vascular dementia
  • Track 4-2Anti psychotic medications
  • Track 4-3Palliative care in vascular dementia
  • Track 4-4Autophagy
  • Track 4-5Synucleinopathies
Amyloid imaging is a technique performed in nuclear medicine. It uses PET ligands that allow in vivo detection of amyloid plaques, a core pathologic feature of Alzheimer disease  and dementia.
  • Track 5-1Beta amyloid protein
  • Track 5-2Cerebral amyloid angiopathy
  • Track 5-3Cerebral amyloid angiopathy
  • Track 5-4Normal pressure hydrocephalus
  • Track 5-5FDG-PET
  • Track 5-6Amyloid Immunotherapy
Vascular dementia is the broad term for dementia associated with problems of circulation of blood to the brain. There are a number of different types of Vascular dementia. Two of the most common are Multi-infarct dementia and Binswanger's disease. The multi-infarct dementia (MID) and vascular intellectual impedance is dementia caused by issues in the supply of blood to the mind, normally a progression of minor strokes. People with vascular dementiagive dynamic subjective hindrance, intensely or sub acutely as in mellow psychological debilitation, every now and again step-wise, after various cerebrovascular occasions (strokes). A few people may seem to enhance amongst occasions and decrease after more noiseless strokes. A quickly decaying condition may prompt demise from a stroke, coronary illness, or infection. Vascular dementia can be caused by ischemic or hemorrhagic infarcts influencing numerous mind regions, including the foremost cerebral supply route domain, the parietal projections, or the cingulate gurus.
  • Track 6-1Vascular dementia prognosis
  • Track 6-2Young onset dementia
  • Track 6-3Multi-infarct dementia
  • Track 6-4Parkinson dementia
  • Track 6-5Advances in vascular dementia therapy
Alzheimer's disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. AD begins slowly. It first involves the parts of the brain that control thought, memory and language. People with AD may have trouble remembering things that happened recently or names of people they know. A related problem, mild cognitive impairment (MCI), causes more memory problems than normal for people of the same age. Many, but not all, people with MCI will develop AD.
  • Track 7-1Stages of Alzheimer
  • Track 7-2Diagnosis of alzheimers
  • Track 7-3Risk factors of alzheimers
  • Track 7-4Clinical studies of alzheimers
  • Track 7-5Treatments of alzheimers
Brain Diseases come in different forms of Infections, trauma, stroke, seizures, and tumors are some of the major categories of brain diseases. Here's an overview of various diseases of the brain
  • Track 8-1Migraine
  • Track 8-2Brain abscess
  • Track 8-3Trauma
  • Track 8-4Seizures
  • Track 8-5Encephalitis
  • Track 8-6Arteriovenous malformation
  • Track 8-7Bipolar disorder
  • Track 8-8Motor neuron disease
  • Track 8-9Attention deficit hyperactivity disorder
Almost 42% of people over the age of 64 experience some form of memory loss. When there is no underlying medical condition causing this memory loss, it is known as "age-associated memory impairment," which is considered a part of the normal aging process.
  • Track 9-1Neuro-anatomical changes in ageing
  • Track 9-2Risk factors of cognitive decline
  • Track 9-3Granulovacuolar degeneration
  • Track 9-4Changes in cerebral cortical microvasculature
  • Track 9-5Advances of research in ageing and dementia
Dementia care management was provided at the homes of patients with dementia. Dementia care management is a model of collaborative care, defined as a complex intervention aiming to provide optimal treatment and care for patients with dementia and support caregivers using a computer-assisted assessment determining a personalized array of intervention modules and subsequent success monitoring. Dementia care management was targeted at the individual patient level and was conducted by nurses with dementia care-specific qualifications.
  • Track 10-1Advances in dementia care management
  • Track 10-2Dementia care management program
  • Track 10-3Undernutrition and obesity in dementia
  • Track 10-4Advance care planning
Caregivers of dementia patients need to understand dementia so that they can understand what the patient is going through. They need to know about underlying diseases, and how these may affect the progress of dementia. They also need to know what sort of behavior to expect. Understanding these helps them plan for their caregiving and to cope with the situation effectively, and with less stress.
  • Track 11-1Dementia nursing care plan
  • Track 11-2Music therapy in dementia
  • Track 11-3Physiotherapy for dementia
  • Track 11-4Clinical features of dementia
  • Track 11-5Therapeutic interventions in dementia
Treatment of dementia begins with the treatment of the underlying disease, where possible. The underlying causes of nutritional, hormonal, tumour-caused or drug-related dementia may be reversible to some extent. For many other diseases, such as Alzheimer's disease (AD), no cure has yet been discovered. However, improvement of cognitive and behavioural symptoms can be achieved through a combination of appropriate medications and other treatments, including psychotherapy.
  • Track 12-1Psychopharmacological treatment
  • Track 12-2Advanced drugs for dementia
  • Track 12-3Cognitive behavioral therapy
  • Track 12-4Family therapy in nursing
The purpose of the session is to consider the use of novel therapeutics for the treatment of dementia and Neurological disorders, Multiple Sclerosis etc. Novel therapeutics includes use of nanotechnology to treat Neurological disorders and CNS disorders and molecular therapeutics based diagnosis etc.
  • Track 13-1Novel therapeutics strategies for Dementia
  • Track 13-2Novel therapeutics technology
  • Track 13-3Novel therapeutics molecule
  • Track 13-4Anti-dementia drugs
  • Track 13-5Novel drug target for the treatment of dementia
One of the greatest challenges, when it comes to Alzheimer’s disease and other dementias, is coping with difficult behaviors. These are symptoms beyond the chronic memory/thinking problems that are the hallmark of dementia. They include problems like:
  • Delusions, paranoid behaviors, or irrational beliefs
  • Agitation (getting “amped up” or “revved up”) and/or aggressive behavior
  • Restless pacing or wandering
  • Disinhibited behaviors, which means saying or doing socially inappropriate things
  • Sleep disturbances
  • Track 14-1Antipsychotics
  • Track 14-2Benzodiazepines
  • Track 14-3Mood-stabilizers
  • Track 14-4Anti-depressants
  • Track 14-5Dementia drugs
It is a branch of Medical Sciences majorly deals with Neuro tumors. Deals with Studies related to Brain and Spinal cord neoplasms. Neuro-oncology and Pediatric Neuro-oncology are the two different Concepts that differentiate the determining methodology of Neuro tumors. Neuro-oncology mainly includes especially related topics like Radiation therapy, Neurosurgery, Neuroimaging, social, Psychological, Neuropathology and psychiatric aspects.
  • Track 15-1Signs and symptoms of dementia
  • Track 15-2Spine Cancer and Spine Cancer Treatment
  • Track 15-3Glioblastoma
  • Track 15-4Meningioma
  • Track 15-5Brain Stem Tumors
  • Track 15-6Malignant Brain Cancers and Brain Metastasis
  • Track 15-7Pediatric Neuro Oncology
  • Track 15-8Astrocytoma
  • Track 15-9Neurotoxicity
Some risk factors for dementia, such as age and genetics, cannot be changed. But researchers continue to explore the impact of other risk factors on brain health and prevention of dementia. Dementia is hard to prevent, because what causes it often is not known. But people who have dementia caused by stroke may be able to prevent future declines by lowering their risk of heart disease and stroke. 
  • Track 16-1Dementia with Lewy bodies
  • Track 16-2Frontotemporal dementia
  • Track 16-3HIV
  • Track 16-4Traumatic brain injury